Hence, assessing the NAT2 SNPs and genotype frequency is a potential host-based omics approach for addressing the inter- and intra-individual isoniazid pharmacokinetic variabilities, isoniazid dose optimization and preventing/reducing the risk of isoniazid-induced ADRs in TB patients for precision therapy of isoniazid [15]. Here, NAT2 is linked to tuberculosis.